Fresenius Medical Care AG's SEC filings document its reporting as a German foreign private issuer with ordinary shares and ADRs listed in Frankfurt and New York. Form 6-K reports furnish quarterly and full-year results, press releases, IFRS financial figures, non-GAAP reconciliations, share buyback disclosures, and material updates affecting the company's kidney care operations.
The filing record also covers the Form 20-F annual report, audited consolidated financial statements, Annual General Meeting materials, ADR voting instruction cards, compensation reporting, Supervisory Board reports, and Management Board explanatory reports under German corporate law. Segment disclosures identify Care Delivery, Care Enablement, Value-Based Care, health care services, and health care products.
Fresenius Medical Care AG appointed Shervin Korangy as CEO and Chair of the Management Board, effective October 12, 2026, succeeding Helen Giza. Korangy, who had served on the Supervisory Board since 2023, resigned from that role in connection with his appointment.
FME said the FME25+ transformation reshaped its organization, streamlined processes and reduced its cost base by around EUR 1.2 billion. The company said its next phase will focus on accelerating long-term profitable growth and advancing innovation. The Supervisory Board identified Ann Custin as a successor to Korangy on the board; court proceedings to appoint her through the end of the current term are to be initiated in due course.
Fresenius Medical Care AG refined its China commercial strategy, focusing on a more localized portfolio, locally relevant innovation and a focused go-to-market approach. China represents approximately 6-7% of the company’s Care Enablement operating segment revenues. The company will focus on technologies for in-center dialysis and critical care, discontinue local production and sales of the 4008A hemodialysis system, and exit its China peritoneal dialysis business while maintaining existing market obligations. It strengthened local leadership, including the appointment of market General Manager Rex Liu.
The portfolio changes are expected to result in approximately €110 million in one-time costs, primarily for impairment charges, scrappage and termination costs. The charge is expected to be recognized as a special item in the third quarter of 2026. The company does not expect the changes to meaningfully affect the future revenue outlook for Care Enablement’s China business.
Fresenius Medical Care AG (FMS) reported the publication of a large multinational real‑world evidence study in the Journal of the American Society of Nephrology comparing high‑volume hemodiafiltration (HVHDF) with conventional high‑flux hemodialysis. The study analyzed outcomes from 19,539 adult dialysis patients treated between 2014 and 2019 in eight European countries using a target trial emulation design. During a median follow‑up of 16 months, hemodiafiltration was associated with a 28% lower relative risk of all‑cause mortality versus high‑flux hemodialysis, with the strongest association in patients achieving convection volumes above 23 liters per session, who had a 33% lower relative risk of death. Fresenius Medical Care highlights this as reinforcing the evidence base for HVHDF and links it to its BEACON‑US initiative to generate U.S.‑specific real‑world evidence as access to HVHDF expands, while noting that the observational nature of the study does not establish causality.
Fresenius Medical Care AG (FMS) disclosed that its major shareholder Fresenius SE & Co. KGaA entered into a Share Purchase Agreement on August 20, 2026 to sell 7,800,000 Shares of Fresenius Medical Care AG in a block trade to J.P. Morgan SE at EUR 39.56 (approximately $46.16) per share in a private placement exempt from registration under the U.S. Securities Act. After this Block Trade, Fresenius SE & Co. KGaA remains the beneficial owner of 67,181,358 Shares, representing about 25.6% of the Company’s outstanding voting shares, based on 262,699,356 Shares outstanding as of August 21, 2026. Fresenius SE & Co. KGaA states that this sale is part of a broader portfolio optimization strategy and that it will continue to review its investment and may consider additional transactions involving the Shares over time.
The Share Purchase Agreement includes a lock-up under which Fresenius SE & Co. KGaA undertook not to dispose of additional Shares or similar securities, subject to exceptions, for a period beginning August 21, 2026 and ending 45 days thereafter without the Purchaser’s prior written consent. Management SE, as general partner of Fresenius SE & Co. KGaA, exercises investment and dispositive power over these Shares and may be deemed their beneficial owner.
Fresenius Medical Care reports mixed interim results for the three and six months ended June 30, 2026. Q2 revenue was €4,861 M, up 1% year over year, with operating income rising 10% to €466 M and margin improving to 9.6%, supported by FME25+ cost savings and favorable U.S. reimbursement effects. Net income was €293 M, while EPS increased to €0.81 helped by substantial share repurchases.
For the first half, revenue declined 2% to €9,473 M, but operating income was broadly stable at €752 M. Care Delivery and Care Enablement benefited from higher prices, TDAPA-related reimbursement and savings, partly offset by lower treatment volumes, inflation, and a €71 M Tavneos-related loss from equity investees. Value-Based Care turned profitable, with member months up 7%. Free cash flow improved to €665 M and the net leverage ratio was 2.6, within the 2.5x–3.0x target, while 27.3 M shares were repurchased across buyback programs.
Fresenius Medical Care has appointed Cassie McLean as a member of the Management Board and Chief Executive Officer of the Care Delivery operating segment, effective 1 August 2026. She succeeds Craig Cordola, who previously served as Chief Executive Officer of Care Delivery.
McLean joined the company in August 2025 as President, Fresenius Kidney Care, and will now have direct accountability for the global clinic business, including Fresenius Kidney Care in the U.S. and Care Delivery International. The role has been reshaped to increase direct accountability for operational execution and business performance. Company leaders highlight her dialysis expertise and leadership experience, and link her appointment to advancing the FME Reignite strategy and mid-term financial aspirations in Care Delivery.
Fresenius Medical Care reported Q2 2026 revenue of EUR 4,861 million, up 1% year-on-year (4% at constant currency), with operating income rising 10% to EUR 466 million. Operating income excluding special items grew 20% to EUR 569 million, lifting the margin to 11.7%. Net income was EUR 218 million (down 3%), but excluding special items increased 13% to EUR 303 million. Basic EPS rose to EUR 0.81, and to EUR 1.13 excluding special items, a 24% increase.
Growth was driven mainly by the Care Delivery segment, FME25+ cost savings and TDAPA reimbursement effects, while Care Enablement faced pricing pressure in China. The FME25+ program delivered EUR 67 million Q2 savings; 2026 savings are expected at EUR 250 million with related one-time costs of EUR 350 million, and total savings of EUR 1.2 billion by end-2027. Operating cash flow increased 11% to EUR 860 million, free cash flow was EUR 625 million, and net leverage remained at 2.6x. The company cancelled 24.8 million shares (8.5% of share capital) and is executing a second buyback program of around EUR 1 billion. Management reaffirmed 2026 guidance for broadly flat revenue and operating income around prior-year levels at constant currency, excluding special items.
Fresenius Medical Care AG reported unaudited second-quarter 2026 results that exceeded capital market expectations on both profit and sales. Operating income excluding special items was EUR 569 million, up 23% at constant currency from the prior year and above the EUR 515 million consensus.
Group revenue rose 4% at constant currency to EUR 4,861 million, slightly above the EUR 4,792 million consensus. The company confirmed its unchanged financial outlook for the full year 2026, based on constant currency and figures excluding special items.
Fresenius Medical Care is introducing BEACON-US, a comprehensive U.S. research initiative to expand clinical and real-world evidence for patients receiving online-hemodiafiltration (HDF). The program supports the ongoing rollout of high-volume hemodiafiltration (HVHDF) and is intended to help clinicians, patients, and healthcare systems understand how the therapy performs in routine practice.
Early U.S. experience with HVHDF is described as encouraging, with data showing 40% fewer muscle cramps and more than 70% of AutoSub plus treatments already reaching the HVHDF target of at least 23 liters of convective volume per session. Observations indicate improved achievement of dialysis adequacy targets (Kt/V), higher convective volumes without longer treatment times, and reduced water consumption, while clinicians report workflow simplification. Internationally, evidence including the CONVINCE trial reported a 23% lower risk of death for HVHDF versus conventional high-flux hemodialysis. Fresenius Medical Care serves approximately 290,000 patients in 3,539 clinics worldwide.
BlackRock, Inc. reports beneficial ownership of common stock of Fresenius Medical Care AG on Schedule 13G. BlackRock holds 13,447,914 shares, representing 5.00% of the outstanding common stock as of June 30, 2026.
BlackRock has sole voting power over 12,463,277 shares and sole dispositive power over all 13,447,914 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no single client exceeds five percent ownership of the class.